Source: NDTV
Introduction
Veteran actor Mukesh Khanna has publicly endorsed the recent regulatory crackdown on high-profile Bollywood stars regarding their participation in surrogate advertising. The controversy centers on the Maharashtra Food and Drug Administration (FDA) issuing formal show-cause notices to Shah Rukh Khan, Ajay Devgn, and Tiger Shroff.
The regulatory action, spearheaded by the state's food safety authorities, targets the actors for their involvement in a promotional campaign for Vimal's cardamom (elaichi) line. Khanna, a vocal critic of such endorsements, has publicly supported the initiative, arguing that these advertisements serve as a gateway for promoting products like pan masala, which are prohibited within the state of Maharashtra.
What Happened
The Maharashtra FDA, under the leadership of official Tukaram Mundhe, recently escalated its oversight of celebrity endorsements by serving legal notices to three of the industry's most recognizable faces. The regulatory body is challenging the legitimacy of advertisements that ostensibly promote cardamom but are widely viewed as surrogate marketing for pan masala brands.
In a direct response to the regulatory move, Mukesh Khanna took to social media to express his solidarity with the FDA. In a video posted to his Instagram account, the actor questioned why these prominent figures, who present themselves as moral role models, would choose to participate in campaigns that he believes mislead the public.
Background
The core of the dispute involves a 2024 advertising campaign that featured Shah Rukh Khan, Ajay Devgn, and Tiger Shroff. While the commercials marketed Vimal-branded cardamom, the FDA maintains that such campaigns are designed to indirectly promote pan masala products, which are subject to strict bans and health-related restrictions in Maharashtra.
Khanna’s critique highlights a long-standing frustration regarding the influence of celebrity culture on public health. He argued that these actors hold a significant responsibility to their audience and should be held accountable for the messages they disseminate, regardless of the specific product being advertised in the spot.
Key Details
The regulatory notices issued by the FDA demand immediate compliance and transparency from the involved parties. The following table outlines the key aspects of the ongoing regulatory investigation into the promotional activities of the actors.
| Regulatory Requirement | Description of Mandate |
|---|---|
| Campaign Discontinuation | Actors must immediately cease their participation in the Vimal promotional campaign. |
| Content Removal | All promotional material related to the advertisements must be deleted from official social media channels. |
| Documentation Submission | The FDA has requested copies of endorsement contracts, campaign briefs, and payment structures. |
| Compliance Proof | Actors are required to provide evidence of due diligence conducted prior to signing the agreements. |
Impact
The involvement of the FDA in scrutinizing celebrity endorsements marks a significant shift in how regulatory bodies interact with the entertainment industry. By demanding access to internal contracts and campaign briefs, authorities are signaling a more aggressive stance toward the practice of surrogate advertising.
For the actors involved, the situation presents a challenge to their public image. Mukesh Khanna has explicitly called for the trio to issue a public apology, suggesting that they have a moral obligation to rectify the situation by acknowledging that the products associated with the brand are not intended for consumption. He further expressed skepticism regarding the delayed nature of the intervention, questioning why such actions were not taken by officials earlier.
What Happens Next
The future of this case remains contingent on the responses provided by the actors to the show-cause notices. The FDA expects full transparency regarding the nature of the deals struck between the celebrities and the manufacturers. As the investigation progresses, the primary focus will be on whether the actors comply with the directive to remove all promotional content and whether they will choose to address the public concerns raised by figures like Mukesh Khanna.
The regulatory body will review the documents and evidence submitted to determine the next steps in their enforcement process. The outcome of this case may set a legal precedent for how future celebrity endorsement deals in the food and tobacco-related sectors are scrutinized by Indian authorities.
